Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity

CD27 is an important co-stimulatory receptor of T cells that can potentially be exploited for immunotherapy. We developed a human IgG1 antibody that targets human CD27, and demonstrated its immunostimulatory and antineoplastic activity in various preclinical models. Currently, the antibody (1F5, CDX...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Lawrence J, He, Li-Zhen, Marsh, Henry, Keler, Tibor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937191/
https://www.ncbi.nlm.nih.gov/pubmed/24605266
http://dx.doi.org/10.4161/onci.27255
_version_ 1782305448652701696
author Thomas, Lawrence J
He, Li-Zhen
Marsh, Henry
Keler, Tibor
author_facet Thomas, Lawrence J
He, Li-Zhen
Marsh, Henry
Keler, Tibor
author_sort Thomas, Lawrence J
collection PubMed
description CD27 is an important co-stimulatory receptor of T cells that can potentially be exploited for immunotherapy. We developed a human IgG1 antibody that targets human CD27, and demonstrated its immunostimulatory and antineoplastic activity in various preclinical models. Currently, the antibody (1F5, CDX-1127) is being tested in patients affected by advanced malignancies.
format Online
Article
Text
id pubmed-3937191
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-39371912014-03-06 Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity Thomas, Lawrence J He, Li-Zhen Marsh, Henry Keler, Tibor Oncoimmunology Author's View CD27 is an important co-stimulatory receptor of T cells that can potentially be exploited for immunotherapy. We developed a human IgG1 antibody that targets human CD27, and demonstrated its immunostimulatory and antineoplastic activity in various preclinical models. Currently, the antibody (1F5, CDX-1127) is being tested in patients affected by advanced malignancies. Landes Bioscience 2014-01-01 /pmc/articles/PMC3937191/ /pubmed/24605266 http://dx.doi.org/10.4161/onci.27255 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Thomas, Lawrence J
He, Li-Zhen
Marsh, Henry
Keler, Tibor
Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
title Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
title_full Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
title_fullStr Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
title_full_unstemmed Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
title_short Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
title_sort targeting human cd27 with an agonist antibody stimulates t-cell activation and antitumor immunity
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937191/
https://www.ncbi.nlm.nih.gov/pubmed/24605266
http://dx.doi.org/10.4161/onci.27255
work_keys_str_mv AT thomaslawrencej targetinghumancd27withanagonistantibodystimulatestcellactivationandantitumorimmunity
AT helizhen targetinghumancd27withanagonistantibodystimulatestcellactivationandantitumorimmunity
AT marshhenry targetinghumancd27withanagonistantibodystimulatestcellactivationandantitumorimmunity
AT kelertibor targetinghumancd27withanagonistantibodystimulatestcellactivationandantitumorimmunity

Ejemplares similares